Research Topics
| I HyodoSummaryAffiliation: National Shikoku Cancer Center Country: Japan Publications
| Collaborators
|
Detail Information
Publications
Psychological impact of informed consent in hospitalized cancer patients. A sequential study of anxiety and depression using the hospital anxiety and depression scaleI Hyodo
Department of Internal Medicine, National Shikoku Cancer Center Hospital, 13 Horinouchi, Matsuyama, Ehime 790 0007, Japan
Support Care Cancer 7:396-9. 1999..Physicians should be aware of these facts and pay special attention to their patients' psychological distress in routine clinical practice...- A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient settingI Hyodo
Department of Internal Medicine, National Shikoku Cancer Center, 13 Horinouchi, 790 0007, Matsuyama, Japan
Eur J Cancer 39:2328-33. 2003..Oral S-1 with weekly cisplatin is a feasible and promising combination regimen that is appropriate for an outpatient setting. A randomised phase II study comparing this combination with S-1 alone in chemo-nai;ve patients is warranted... - Nationwide survey on complementary and alternative medicine in cancer patients in JapanIchinosuke Hyodo
Medical Oncology Division, National Shikoku Cancer Center, Horinouchi 13, Matsuyama, 790 0007 Ehime, Japan
J Clin Oncol 23:2645-54. 2005..To determine the prevalence of use of complementary and alternative medicine (CAM) by patients with cancer in Japan, and to compare the characteristics of CAM users and CAM nonusers... - Perceptions and attitudes of clinical oncologists on complementary and alternative medicine: a nationwide survey in JapanIchinosuke Hyodo
Department of Medical Oncology, National Shikoku Cancer Center, Ehime, Japan
Cancer 97:2861-8. 2003..The authors performed a cross-sectional survey to evaluate the perceptions and attitudes of Japanese clinical oncologists toward cancer CAM... 
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancerW Koizumi
Department of Internal Medicine, Kitasato University School of Medicine, 2 1 1 Asamizodai, Sagamihara shi, Kanagawa, Japan
Ann Oncol 21:766-71. 2010..This study aimed to evaluate the safety and efficacy of S-1 combined with oral leucovorin (LV) to enhance antitumor activity in chemotherapy-naive patients with mCRC...- Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resectionJ Nasu
Dept of Internal Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
Endoscopy 37:990-3. 2005..The incidence and characteristics of metachronous multiple gastric cancers were investigated in a retrospective study in patients with early gastric cancer after EMR treatment... - Current status of cancer patients' perception of alternative medicine in Japan. A preliminary cross-sectional surveyK Eguchi
Department of Medical Oncology, National Shikoku Cancer Center, Ehime Prefecture, Japan
Support Care Cancer 8:28-32. 2000..Issues that we have to solve are concerned with the education of cancer patients, lay people and physicians on the meaning and role of alternative medicine and on the necessity for scientific evaluation of medical treatments in Japan... - Serum soluble Fas antigen in gastric MALT (mucosa-associated lymphoid tissue) lymphoma patientsT Doi
Dept of Internal Medicine, National Shikoku Cancer Center Hospital, Matsuyama, Japan
J Exp Clin Cancer Res 18:343-5. 1999.... - Predictive factors of lymph node metastasis in patients with undifferentiated early gastric cancersJunichirou Nasu
Department of Internal Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan
J Clin Gastroenterol 40:412-5. 2006.... - The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridineTomohiro Nishina
Department of Medical Oncology, National Shikoku Cancer Center, 13 Horinouchi, Matsuyama, Ehime 790 0007, Japan
Eur J Cancer 40:1566-71. 2004..183 days, P = 0.047). The efficacy of 5'-DFUR could be optimised by preselecting patients with high TP/ DPD ratios in their tumour tissues, and this would be applicable to the treatment with capecitabine... - Routine endoscopy using a magnifying endoscope for gastric cancer diagnosisH Tajiri
Department of Internal Medicine, National Shikoku Cancer Center, Ehime, Japan
Endoscopy 34:772-7. 2002..The aim of this prospective study was to clarify the relationship between the fine mucosal patterns of gastric lesions and histological findings, and also to evaluate the usefulness of magnifying endoscopy during routine endoscopy... - Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactionsY Yamada
Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
Ann Oncol 12:1133-7. 2001.... - Efficacy of clinical pathway for the management of mucosal gastric carcinoma treated with endoscopic submucosal dissection using an insulated-tip diathermic knifeShoji Hirasaki
Department of Internal Medicine, Shikoku Cancer Center, Matsuyama
Intern Med 43:1120-5. 2004.... - A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancerToshikazu Moriwaki
Department of Medical Oncology, National Shikoku Cancer Center, 13 Horinouchi, Matsuyama, Ehime 790-0007, Japan
Cancer Chemother Pharmacol 56:138-44. 2005..The results of this phase I study are encouraging and a phase II trial is thus warranted... - Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 TriaTakekazu Yamao
Department of Internal Medicine, Cancer Institute Hospital, Tokyo, Japan
Jpn J Clin Oncol 34:316-22. 2004..2-52.5%). CONCLUSIONS: Sequential MTX/5FU therapy is effective against AGC with malignant ascites with acceptable toxicity and warrants further investigations in a phase III setting... - Gastric cancer concomitant with inflammatory fibroid polyp treated with endoscopic mucosal resection using an insulation-tip diathermic knifeShoji Hirasaki
Department of Internal Medicine, National Shikoku Cancer Center, 13 Horino-uchi, Matsuyama 790-0007
Intern Med 42:259-62. 2003..Adenocarcinoma in the IIc area was present adjacent to the IFP. This may be the first report of gastric cancer concomitant with gastric IFP treated by endoscopic mucosal resection... - Unresectable alpha fetoprotein-producing gastric cancer successfully treated with irinotecan and mitomycin C after S-1 failureKen Hirao
Department of Internal Medicine, National Shikoku Cancer Center, 13 Horino-uchi, Matsuyama 790-0007
Intern Med 43:106-10. 2004..Second line chemotherapy may have contributed to the favorable clinical outcome in this patient... - [Malignant lymphoma with submucosal invasion in the terminal ileum diagnosed with colonoscopy and examined by endoscopic ultrasonography]Shoji Hirasaki
Department of Internal Medicine, National Shikoku Cancer Center
Nippon Shokakibyo Gakkai Zasshi 101:41-6. 2004 - Extragonadal retroperitoneal embryonal carcinoma successfully treated with chemotherapyShoji Hirasaki
Department of Internal Medicine, National Shikoku Cancer Center, 13 Horino-uchi, Matsuyama 790-0007
Intern Med 42:1122-6. 2003..A curative surgical operation revealed that there were no malignant cells in the lung lesions and primary lesion. This patient responded well to chemotherapy and achieved complete remission by chemotherapy... - [Psychological support of cancer patients and their relatives following informed consent]Ichinosuke Hyodo
Department of Internal Medicine, National Shikoku Cancer Center
Nippon Rinsho 61:557-9. 2003 - Unusual metastasis of hepatocellular carcinoma to the esophagusEiji Tsubouchi
Department of Internal Medicine, Shikoku Cancer Center, Matsuyama, Japan
Intern Med 44:444-7. 2005..There were no symptoms due to esophageal tumor. He died of progressive hepatic failure. Cases of premortem-diagnosed esophageal metastasis from HCC are extremely rare... - A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancerIchinosuke Hyodo
Division of Gastroenterology, University of Tsukuba, Tsukuba, Ibaraki 305 8575, Japan
Jpn J Clin Oncol 36:410-7. 2006..Therefore, we performed a phase II study to investigate the 3-week regimen of capecitabine in Japanese patients with metastatic colorectal cancer (MCRC)... - Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatinFumio Nagashima
Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
Jpn J Clin Oncol 35:714-9. 2005..Here, we investigated if these biological markers can predict chemoresponse and survival of unresectable gastric cancer patients treated with irinotecan and cisplatin... - Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancerJunichi Sakamoto
Department of Epidemiological and Clinical Research Information Management, Kyoto University Graduate School of Medicine, Kyoto, Japan
Anticancer Drugs 17:231-6. 2006..We conclude that this 4-week regimen of capecitabine showed promising activity and was well tolerated as first-line therapy for advanced/metastatic gastric cancer. Further investigation of this regimen is warranted... - Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatinNarikazu Boku
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto gun, Shizuoka, Japan
Jpn J Clin Oncol 37:275-81. 2007..The purpose of this study is to confirm our previous results and to compare the significance of those markers between continuous infusion of 5-FU (5-FUci) and FP... - Timing of significant adverse events is essential information during early development of new drugsIchinosuke Hyodo
Int J Clin Oncol 11:69; author reply 69-70. 2006 - [Clinical study of TS-1 therapy for inoperable and recurrent gastric cancer]Toshikazu Moriwaki
Dept. of Internal Medicine, National Shikoku Cancer Center
Gan To Kagaku Ryoho 30:489-94. 2003..These results were similar to those reported in the phase II study for the new drug approval. This study demonstrated the reproducible activity and safety of TS-1 in practice... - Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II studyYashushi Mitachi
Department of Gastroenterology and Medical Oncology, Sendai Kosei Hospital, 4-15, Hirosecho, Aobaku, Sendai, Miyagi 980-0873, Japan
Gastric Cancer 5:160-7. 2002.... - Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) studyMotoki Yoshida
Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Jpn J Clin Oncol 34:654-9. 2004..The aim of this analysis was to investigate prognostic factors for patients with metastatic gastric cancer treated by chemotherapy, and to identify the characteristics of long-term survivors... - How should oncologists face complementary and alternative medicine?Ichinosuke Hyodo
Jpn J Clin Oncol 38:511. 2008 - Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)Atsushi Ohtsu
Division of Gastrointestinal Oncology Digestive Endoscopy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
J Clin Oncol 21:54-9. 2003..To compare fluorouracil (FU) alone with FU plus cisplatin (FP) and with uracil and tegafur plus mitomycin (UFTM) for patients with advanced gastric cancer in a prospective, randomized, controlled trial... 
Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenaseWasaburo Koizumi
Department of Gastroenterology, East Hospital, Kitasato University School of Medicine, Sagamihara City, Kanagawa, Japan
Anticancer Drugs 19:819-24. 2008..028) in patients with TP-positive and DPD-negative tumors (RR=60%, 6/10) than in the remaining patients (RR=13%, 2/15). TP and DPD expression profiles are useful for predicting a response to capecitabine...- A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trialTetsuya Hamaguchi
Division of Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan
Jpn J Clin Oncol 38:432-7. 2008..Therefore, we conducted a phase II study to evaluate the efficacy and toxicity of sequential treatment with methotrexate (MTX) and also 5-FU as second-line chemotherapy in patients with advanced gastric cancer... - [S-1 combined with weekly dosing of cisplatin for metastatic gastric cancer]Ichinosuke Hyodo
Division of Gastroenterology, University of Tsukuba, Japan
Gan To Kagaku Ryoho 33:64-7. 2006..The median survival was 11 months, despite including 11 pre-treated patients. S-1 given with weekly cisplatin was a feasible and promising combination regimen for an outpatient setting... - Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancerHiromi Sakamoto
Nat Genet 40:730-40. 2008..90, 95% CI = 1.56-2.33, P = 8.01 x 10(-11)). The polymorphism of the PSCA gene, which is possibly involved in regulating gastric epithelial-cell proliferation, influences susceptibility to diffuse-type gastric cancer... - Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issueIchinosuke Hyodo
J Gastroenterol 41:504-6. 2006 - [A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer]Mitsukuni Suenaga
Cancer Institute Hospital, Japanese Foundation for Cancer Research
Gan To Kagaku Ryoho 35:255-60. 2008..There were no treatment-related deaths. Neuro-sensory toxicity was a highly-frequent adverse event (78.9%), but no grade 3/4 neurotoxicity was seen. The FOLFOX4 regimen was acceptable to Japanese patients with ACRC in at least 3 cycles... - Geranylgeranylacetone protects the human gastric mucosa from diclofenac-induced injury via induction of heat shock protein 70Akinori Yanaka
Department of Gastroenterology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan
Digestion 75:148-55. 2007..This study was conducted to determine whether a clinical dose of GGA protects the human gastric mucosa from diclofenac (DIC)-induced gastric mucosal injury... - [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer]Toshikazu Moriwaki
Dept of Internal Medicine, National Hospital Organization Shikoku Cancer Center
Gan To Kagaku Ryoho 34:2249-53. 2007..Non-hematological toxicities were mild. The median survival time was 11 months. The 1-year survival rate was 34%. This study showed the activity and safety of FOLFIRI in practice... - [Standard chemotherapy for colonic neoplasms]Ichinosuke Hyodo
Nippon Naika Gakkai Zasshi 96:283-8. 2007 - Artificial hydration therapy, laboratory findings, and fluid balance in terminally ill patients with abdominal malignanciesTatsuya Morita
Department of Palliative and Supportive Care, Palliative Care Team and Seirei Hospice, Seirei Mikatahara General Hospital, Hamamatsu, Japan
J Pain Symptom Manage 31:130-9. 2006..Calculated fluid balance is not an appropriate alternative to direct monitoring of patient symptoms. More studies are needed to determine the clinical efficacy of artificial hydration for terminally ill cancer patients... - Incidence and underlying etiologies of bronchial secretion in terminally ill cancer patients: a multicenter, prospective, observational studyTatsuya Morita
Seirei Hospice, Seirei Mikatabara Hospital, Hamamatsu, Shizuoka, Japan
J Pain Symptom Manage 27:533-9. 2004..Etiology-based classification of bronchial secretion is useful to identify the most suitable palliative treatments and to clarify treatment efficacy in each specific pathophysiology... - Seronegative alpha-fetoprotein-producing early gastric cancer treated with endoscopic mucosal resection and additional surgeryShoji Hirasaki
Department of Internal Medicine, Shikoku Cancer Center, 13 Horino-uchi, Matsuyama 790-0007
Intern Med 43:926-30. 2004..This patient remains alive without disease for 3 years after surgery... - [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient]Yasuo Shima
Palliative Care Unit, National Cancer Center Hospital East
Gan To Kagaku Ryoho 31:1377-82. 2004..4%) showed an excess of liver enzymes but no clinically suspected adverse effect was observed. Octreotide is effective and well tolerated in terminally ill cancer patients with malignant bowel obstruction... - [Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic cancer]Toshikazu Moriwaki
Dept of Internal Medicine, National Hospital Organization Shikoku Cancer Center
Gan To Kagaku Ryoho 31:1373-6. 2004..Non-hematological toxicities were mild. The median survival time was 4.8 months. One-year survival rate was 15%. This study showed the reproducible activity and safety of GEM in practice... - [Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer]Tomohiro Nishina
Dept. of Internal Medicine, National Hospital Organization Shikoku Cancer Center
Gan To Kagaku Ryoho 31:1361-4. 2004..This retrospective study demonstrated the reproducible activity and safety of CPT-11 for the treatment of fluoropyrimidine-resistant advanced colorectal cancer in clinical practice... - Multiple synchronous early gastric carcinoma with seven lesionsShoji Hirasaki
J Gastroenterol 38:1194. 2003 - Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancerYasuhide Yamada
Division of Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan
Cancer Chemother Pharmacol 52:125-30. 2003..We evaluated the antitumor activity and toxicity of a combination of irinotecan and MMC in patients with metastatic colorectal cancer resistant to fluoropyrimidines... - A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703)Atsushi Ohtsu
Division of Gastrointestinal Oncology Digestive Endoscopy, National Cancer Center Hospital East, Kashiwanoha, Kashiwa, Japan
Jpn J Clin Oncol 33:28-32. 2003....